Experimental immune cell therapy for AML shows promise but trial halted early

NCT ID NCT04511130

Terminated Disease control Sponsor: Marker Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a treatment called MT-401, which uses specially trained immune cells from a donor to fight acute myeloid leukemia (AML) after a stem cell transplant. The goal was to see if these cells could prevent or treat relapse. The trial enrolled 92 people but was stopped early. The approach aims to control the disease, not cure it, as patients still need ongoing monitoring and care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA STEM CELL TRANSPLANTATION

Contacts and locations

Locations

Baylor College of Medicine

Houston, Texas, 77030, United States
City of Hope National Medical Center

Duarte, California, 91010, United States
Cleveland Clinic Taussig Cancer Center

Cleveland, Ohio, 44195, United States
John Theurer Cancer Center at Hackensack UMC

Hackensack, New Jersey, 07601, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Mayo Clinic Cancer Center-Rochester

Rochester, Minnesota, 55905, United States
Mayo Clinical Cancer Center-Florida

Jacksonville, Florida, 32224, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Montefiore Medical Center

The Bronx, New York, 10467, United States
Moores Cancer Center at University of Californa San Diego

La Jolla, California, 92093, United States
UCLA Department of Medicine

Los Angeles, California, 90095, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35249, United States
University of Chicago

Chicago, Illinois, 77027, United States
University of Iowa Hospitals & Clinics

Iowa City, Iowa, 52242, United States
Weill Cornell Medicine | NewYork-Presbyterian

New York, New York, 10027, United States
Winship Cancer Institute of Emory University

Atlanta, Georgia, 303222, United States
Yale Cancer Center

New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.